Healthcare & Life Sciences
TriArm Therapeutics
United States
aliveseries-a
series-a
Stage
1
Investors
About
TriArm Therapeutics develops autologous, non-viral CAR-T and cell therapy manufacturing technologies that increase the yield of immune-naïve, potent, and persistent T cells, while reducing vein-to-vein delivery times, costs, and cytokine storm risk.
Explore TriArm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.